Literature DB >> 17205522

Low adiponectin levels are associated with renal cell carcinoma: a case-control study.

Themistoklis N Spyridopoulos1, Eleni Th Petridou, Alkistis Skalkidou, Nick Dessypris, George P Chrousos, Christos S Mantzoros.   

Abstract

Adiponectin is a novel endogenous insulin sensitizer, secreted by mature adipocytes. Circulating levels of adiponectin are inversely associated with obesity and insulin resistance. Because obesity is a risk factor for renal cell carcinoma (RCC), we hypothesized that low adiponectin levels are associated with RCC. To evaluate this hypothesis, we conducted a case- control study of 70 patients with histologically confirmed RCC and 280 healthy controls matched by gender, age and county of residence. Study subjects were interviewed and blood samples were collected during a 32-month period in Athens, Greece. Serum adiponectin levels were statistically, significantly and inversely associated with RCC when compared with controls (OR=0.76, p=0.05) and this association remained practically unchanged after controlling for BMI; the introduction of waist to hip ratio along with adiponectin in the multiple logistic regression analysis model rendered the association between adiponectin and RCC risk insignificant, indicating that altered levels of adiponectin may mediate the effect of central or intra-abdominal obesity on RCC. Prospective studies as well as studies exploring underlying mechanisms are needed to fully explore the role of adiponectin in predicting future risk of RCC in humans. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17205522     DOI: 10.1002/ijc.22526

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  37 in total

1.  Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies.

Authors:  Nicholas Mitsiades; Kalliopi Pazaitou-Panayiotou; Konstantinos N Aronis; Hyun-Seuk Moon; John P Chamberland; Xiaowen Liu; Kalliope N Diakopoulos; Vasileios Kyttaris; Vasiliki Panagiotou; Geetha Mylvaganam; Sofia Tseleni-Balafouta; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2011-09-21       Impact factor: 5.958

2.  Adiponectin receptors are downregulated in human gastric cancer.

Authors:  Kensuke Otani; Joji Kitayama; Takao Kamei; Daisuke Soma; Hideyo Miyato; Toshimasa Yamauchi; Takashi Kadowaki; Hirokazu Nagawa
Journal:  J Gastroenterol       Date:  2010-03-25       Impact factor: 7.527

Review 3.  Adiponectin as a Potential Therapeutic Target for Prostate Cancer.

Authors:  Hanuma Kumar Karnati; Manas Kumar Panigrahi; Yazhou Li; David Tweedie; Nigel H Greig
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

4.  Hypertension and obesity and the risk of kidney cancer in 2 large cohorts of US men and women.

Authors:  Kristen M Sanfilippo; Kathleen M McTigue; Christian J Fidler; James D Neaton; Yuefang Chang; Linda F Fried; Simin Liu; Lewis H Kuller
Journal:  Hypertension       Date:  2014-03-17       Impact factor: 10.190

5.  Comparison of adiponectin concentration between pancreatic cancer and colorectal cancer.

Authors:  Jean Marc Phelip; Serban Bageacu; Mathieu Baconnier; Gabriele Barabino; Emilie Del Tedesco; Pierre Yves Benhamou; Xavier Roblin
Journal:  J Gastrointest Oncol       Date:  2011-12

6.  Adiponectin receptor 2 is negatively associated with lymph node metastasis of colorectal cancer.

Authors:  Masaya Hiyoshi; Nelson H Tsuno; Kensuke Otani; Kazushige Kawai; Takeshi Nishikawa; Yasutaka Shuno; Kazuhito Sasaki; Kumiko Hongo; Manabu Kaneko; Eiji Sunami; Koki Takahashi; Hirokazu Nagawa; Joji Kitayama
Journal:  Oncol Lett       Date:  2012-02-07       Impact factor: 2.967

Review 7.  Adiponectin, driver or passenger on the road to insulin sensitivity?

Authors:  Risheng Ye; Philipp E Scherer
Journal:  Mol Metab       Date:  2013-04-19       Impact factor: 7.422

8.  Underactivation of the adiponectin-adiponectin receptor 1 axis in clear cell renal cell carcinoma: implications for progression.

Authors:  Nir Kleinmann; Wilhelmina C M Duivenvoorden; Sarah N Hopmans; Laura K Beatty; Shengjun Qiao; Daniel Gallino; Sarka Lhotak; Dean Daya; Athanasios Paschos; Richard C Austin; Jehonathan H Pinthus
Journal:  Clin Exp Metastasis       Date:  2013-10-05       Impact factor: 5.150

9.  Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study.

Authors:  Maria Dalamaga; Ilias Migdalis; Jessica L Fargnoli; Evangelia Papadavid; Erica Bloom; Nicholas Mitsiades; Konstantinos Karmaniolas; Nicolaos Pelecanos; Sofia Tseleni-Balafouta; Amalia Dionyssiou-Asteriou; Christos S Mantzoros
Journal:  Cancer Causes Control       Date:  2008-12-03       Impact factor: 2.506

Review 10.  Metabolic syndrome and cancer.

Authors:  Pooja Pothiwala; Sushil K Jain; Subhashini Yaturu
Journal:  Metab Syndr Relat Disord       Date:  2009-08       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.